Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference
13 nov. 2018 08h45 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
09 nov. 2018 16h20 HE
|
Abeona Therapeutics Inc.
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage...
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
05 nov. 2018 07h00 HE
|
Abeona Therapeutics Inc.
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10...
Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
12 sept. 2018 08h45 HE
|
Abeona Therapeutics Inc.
Clinical trial for ABO-101 (AAV-NAGLU) marks the 2nd MPS III program in EuropeCompany plans to initiate additional clinical sites in European countries including France, Germany and the United Kingdom...
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
06 juin 2018 08h45 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 06, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
31 mai 2018 08h45 HE
|
Abeona Therapeutics Inc.
-- The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases -- Ribbon-cutting ceremony of gene and cell...
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
18 mai 2018 09h25 HE
|
Abeona Therapeutics Inc.
ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver...
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
14 mai 2018 08h15 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 14, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
23 avr. 2018 08h15 HE
|
Abeona Therapeutics Inc.
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics...
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
16 mars 2018 17h10 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...